Eidolon Selected for VCC 2025 Cohort

We’re thrilled to announce that Eidolon Therapeutics has been selected as one of the Top 25 startups in the Venture Catalyst Challenge (VCC) 2025 — Imperial College London’s flagship entrepreneurship programme run by the Imperial Enterprise Lab.

The VCC supports some of the UK’s most promising early-stage ventures, providing mentorship, funding opportunities, and access to Imperial’s vibrant innovation ecosystem.

Eidolon Therapeutics is developing breakthrough technology to make immunotherapy effective against cancers where it currently falls short, by combining innovations in microbial genome mining, live-cell imaging, and AI-driven drug discovery.

“Eidolon Therapeutics is the second start-up to come out of the lab. Super excited about developing new tech to make immunotherapy effective against cancers where it currently doesn’t work. Eidolon is combining the mining of microbial genomes, live cell imaging, and AI to develop these new therapies.”

– Professor Chris Bakal, Co-founder of Eidolon Therapeutics.

Over the next few months, Eidolon will participate in the VCC’s accelerator journey alongside an inspiring cohort of innovators across AI, medtech, climate, and deep tech.

Stay tuned as we share updates from our journey in the Venture Catalyst Challenge 2025.